Immunity after HPV Vaccination in Patients after Sexual Initiation

Area of Science:

• Gynecology
• Immunology
• Oncology

Background:

• Human papillomavirus (HPV) vaccination is crucial for preventing precancerous lesions and HPV-related cancers.
• Current research primarily focuses on the effectiveness of HPV vaccination in juvenile populations.
• Limited data exists regarding the impact of HPV vaccination in sexually active individuals or those with existing cervical pathology.

Purpose of the Study:

• To evaluate the immunogenicity of the 9-valent HPV vaccine in healthy individuals and those with diagnosed cervical pathology after sexual initiation.
• To assess the levels of anti-HPV (L1 HPV) antibodies in vaccinated subjects compared to unvaccinated controls.
• To explore the potential benefits of HPV vaccination in a broader patient demographic.

Main Methods:

• Prospective, non-randomized pilot study over 12 months with 89 enrolled subjects.
• Enzyme-linked immunosorbent assay (ELISA) used to quantify IgG class antibodies against HPV.
• Comparison of antibody levels between vaccinated and unvaccinated individuals.

Main Results:

• Significantly elevated levels of anti-HPV antibodies were observed in vaccinated individuals compared to the unvaccinated control group.
• The study demonstrated a robust immune response to the 9-valent HPV vaccine in the studied population.
• Higher antibody titers suggest successful B-cell response and potential for protection.

Conclusions:

• HPV vaccination may be beneficial for individuals after sexual initiation, including those with pre-existing HPV or SIL infections.
• The 9-valent vaccine elicits a significant antibody response in a diverse patient group.
• Further research is warranted to confirm the long-term efficacy and clinical outcomes of HPV vaccination in these populations.